In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

King buys Jones in $3.2bn stock transaction

Executive Summary

King Pharmaceuticals is acquiring Jones Pharma in an all-stock pooling-of-interests transaction that values Jones at $3.2bn. Each common share of Jones will be exchanged for 1.125 shares of King common, a premium of (pr)16% based on their 10-day pre-announcement market averages.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Payment Includes Stock
    • Includes Contract

Related Companies

Advertisement
UsernamePublicRestriction

Register